

# 2019 Performance Measures Crosswalk

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre-population Source from 2018 UDS*	Denominator Description	Denominator Pre-population Source from 2018 UDS*
<b>Clinical Performance Measures</b>						
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) ( <a href="#">CMS122v7</a> )	Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period	No	Patients whose most recent HbA1c level performed during the measurement period is > 9.0% or who had no test conducted during the measurement period	T7, Li, C3A * (T7, Li, C3F / T7, Li, C3B)	Only patients 18-75 years of age with a diagnosis of Type 1 or Type 2 diabetes should be included in the denominator of this measure; patients with a diagnosis of secondary diabetes due to another condition should not be included	T7, Li, C3A
Screening for Depression and Follow-up Plan ( <a href="#">CMS2v8</a> )	Percentage of patients 12 years of age and older screened for depression on the date of the visit using an age appropriate standardized depression screening tool AND, if the screening is positive, a follow-up plan is documented on the date of the positive screening	No	Patients screened for depression on the date of the medical visit using an age appropriate standardized screening tool AND, if positive, a follow-up plan is documented on the date of the positive screening	T6B, L21, CA * (T6B, L21, CC / T6B, L21, CB)	Patients 12 years of age and older with at least one medical visit during the measurement period, excluding patients with an active diagnosis of depression or bipolar disorder; patients who refuse to participate; patients who are in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status; or situations where the patient's functional capacity or motivation to	T6B, L21, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
					improve may impact the accuracy of results of standardized depression assessment tools	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (CMS155v7)	Percentage of patients 3-17 years of age who had a medical visit and evidence of height, weight, and BMI percentile documentation, and who had documentation of (1) counseling for nutrition, and (2) counseling for physical activity during the measurement period	No	Patients who had their BMI percentile (not just BMI or height and weight) documented during the measurement period, and who had documentation of (1) counseling for nutrition and (2) counseling for physical activity during the measurement period	T6B, L12, CA * (T6B, L12, CC / T6B, L12, CB)	Patients 3 - 17 years of age with at least one medical visit during the measurement period, excluding patients with a diagnosis of pregnancy or in hospice care during the measurement period	T6B, L12, CA
Body Mass Index (BMI) Screening and Follow-up Plan (CMS69v7)	Percentage of patients 18 years of age and older with a BMI documented during the most recent visit or within the previous 12 months to that visit, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the visit or during the previous 12 months of that visit	No	Patients with a documented BMI during the most recent visit or during the previous twelve months of that visit, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the visit or during the previous 12 months of the current visit.  Normal Parameters: Age 18 years and older with a BMI greater than or equal to 18.5 and less than 25 kg/m <sup>2</sup>	T6B, L13, CA * (T6B, L13, CC / T6B, L13, CB)	Patients age 18 years of age and older with at least one medical visit during the measurement period, excluding patients who are: pregnant; receiving palliative care; who refuse measurement of height and/or weight or follow-up; patients with a documented medical reason during the visit or within 12 months of the visit; or patients in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status	T6B, L13, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
Controlling High Blood Pressure (CMS165v7)	Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (less than 140/90 mm Hg) during the measurement period	No	Patients whose blood pressure at the most recent visit is adequately controlled (systolic blood pressure < 140 mm Hg and diastolic blood pressure < 90 mm Hg) during the measurement period	T7, Li, C2A * (T7, Li, C2C / T7, Li, C2B)	Patients 18-85 years of age who had a diagnosis of essential hypertension within the first six months of the measurement period or any time prior to the measurement period with a medical visit during the measurement period, excluding patients with evidence of end stage renal disease (ESRD), dialysis, or renal transplant before or during the measurement period; patients who were pregnant during the measurement period; or patients who were in hospice care during the measurement period	T7, Li, C2A
Low Birth Weight	Percentage of babies of health center prenatal care patients born whose birth weight was below normal (less than 2,500 grams)	No	Babies born with a birth weight under 2,500 grams	T7, Li, C1b + T7, Li, C1c	Babies born during the measurement period to prenatal care patients, excluding stillbirths and miscarriages	T7, Li, C1b + T7, Li, C1c + T7, Li, C1d
Early Entry into Prenatal Care	Percentage of prenatal care patients who entered prenatal care during their first trimester	No	Women beginning prenatal care at the health center or a referral provider, or with another prenatal provider during their first trimester	T6B, L7, CA + T6B, L7, CB	Women seen for prenatal care during the measurement period	T6B, L7, CA + T6B, L8, CA + T6B, L9, CA + T6B, L7, CB + T6B, L8, CB + T6B, L9, CB

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
Childhood Immunization Status (CMS117v7)	Percentage of children 2 years of age who had four diphtheria, tetanus, and acellular pertussis (DTaP); three polio (IPV), one measles, mumps, and rubella (MMR); three H influenza type B (HiB); three Hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one Hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday	No	Children who have evidence showing they received recommended vaccines, had documented history of the illness, a seropositive test result, or an allergic reaction to the vaccine by their second birthday	T6B, L10, CA * (T6B, L10, CC / T6B, L10, CB)	Children who turn 2 years of age during the measurement period and who had a medical visit during the measurement period, excluding patients who were in hospice care during the measurement period	T6B, L10, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
Cervical Cancer Screening (CMS124v7)	Percentage of women 21-64 years of age, who were screened for cervical cancer using either of the following criteria: 1) Women age 21-64 who had cervical cytology performed every three years, or 2) Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every five years	No	Women with one or more screenings for cervical cancer, defined by any one of the following: 1) Cervical cytology performed during the measurement period, or the two years prior to the measurement period, for women who are at least 21 years old at the time of the test, or 2) Cervical cytology/human papillomavirus (HPV) co-testing performed during the measurement period, or the four years prior to the measurement period, for women who are at least 30 years old at the time of the test	T6B, L11, CA * (T6B, L11, CC / T6B, L11, CB)	Women 23-64 years of age with a medical visit during the measurement period, excluding women who had a hysterectomy with no residual cervix, or a congenital absence of cervix, or patients who were in hospice care during the measurement period	T6B, L11, CA
Tobacco Use: Screening and Cessation Intervention (CMS138v7)	Percentage of patients 18 years of age and older who were screened for tobacco use one or more times within 24 months AND who received cessation intervention, if defined as a tobacco user	No	Patients who were screened for tobacco use at least once within 24 months before the end of the measurement period AND who received tobacco cessation intervention, if identified as a tobacco user	T6B, L14A, CA * (T6B, L14A, CC / T6B, L14A, CB)	Patients 18 years of age and older seen for at least two medical visits, or at least one preventive medical visit, during the measurement period, excluding documentation of medical reason(s) for not screening for tobacco use OR for not providing tobacco cessation intervention for patients identified as tobacco users	T6B, L14A, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age with a diagnosis of persistent asthma and who were appropriately ordered medication during the measurement period	No	Patients who were ordered at least one prescription for a preferred therapy during the measurement period	T6B, L16, CA * (T6B, L16, CC / T6B, L16, CB)	Patients 5-64 years of age with persistent asthma and who had at least one medical visit during the measurement period, excluding patients with a diagnosis of emphysema, COPD, obstructive chronic bronchitis, cystic fibrosis, or acute respiratory failure that overlaps the measurement period	T6B, L16, CA
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet (CMS164v6)	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and had documentation of use of aspirin or another antiplatelet during the measurement period	No	Patients who had an active medication of aspirin or another antiplatelet during the measurement period	T6B, L18, CA * (T6B, L18, CC / T6B, L18, CB)	Patients 18 years of age and older with a medical visit during the measurement period who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD overlapping the measurement period, excluding patients who had documentation of use of anticoagulant medications overlapping the measurement period, and patients who were in hospice care during the measurement period	T6B, L18, CA
Colorectal Cancer Screening (CMS130v7)	Percentage of patients 50-75 years of age who had appropriate screening for colorectal cancer	No	Patients with one or more screenings for colorectal cancer. Appropriate	T6B, L19, CA * (T6B, L19,	Patients 50-75 years of age with a medical visit during the measurement period, excluding patients with a diagnosis or	T6B, L19, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
			<p>screenings are defined by any one of the following criteria:</p> <ul style="list-style-type: none"> <li>• Fecal occult blood test (FOBT) during the measurement period;</li> <li>• Fecal immunochemical test (FIT)-DNA during the measurement period or the two years prior to the measurement period;</li> <li>• Flexible sigmoidoscopy during the measurement period or the four years prior to the measurement period;</li> <li>• CT colonography during the measurement period or the four years prior to the measurement period; or</li> <li>• Colonoscopy during the measurement period or the nine years prior to the measurement period</li> </ul>	CC/T6B, L19, CB)	past history of total colectomy or colorectal cancer, or patients who were in hospice care during the measurement period	
HIV Linkage To Care	Percentage of patients newly diagnosed with HIV who were seen for follow-up treatment within 90 days of diagnosis	No	Newly diagnosed HIV patients that received treatment within 90 days of diagnosis, including patients who were newly diagnosed by health center providers, and:	T6B, L20, CA * (T6B, L20, CC / T6B, L20, CB)	Patients first diagnosed with HIV by the health center between October 1 of the prior year through September 30 of the current measurement year, and who had at least one	T6B, L20, CA

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre-population Source from 2018 UDS*	Denominator Description	Denominator Pre-population Source from 2018 UDS*
			<ul style="list-style-type: none"> <li>Had a medical visit with a health center provider who initiates treatment for HIV, or</li> <li>Had a visit with a referral resource who initiates treatment for HIV</li> </ul>		medical visit during the measurement period or prior year	
Dental Sealants for Children between 6 -9 Years ( <a href="#">CMS277v0</a> )	Percentage of children, 6- 9 years of age, at moderate to high risk for caries who received a sealant on a permanent first molar during the measurement period	No	Children who received a sealant on a permanent first molar tooth during the measurement period	T6B, L22, CA * (T6B, L22, CC / T6B, L22, CB)	Children 6-9 years of age who had an oral assessment, or comprehensive or periodic oral evaluation dental visit, and are at moderate to high risk for caries, excluding children for whom all first permanent molars are non-sealable	T6B, L22, CA
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease ( <a href="#">CMS347v2</a> )	<p>Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:</p> <ul style="list-style-type: none"> <li>Adults aged <math>\geq</math> 21 years who were previously diagnosed with, or currently have, an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR</li> </ul>	NEW	Patients who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period.	N/A	<p>All patients who meet one or more of the following criteria (considered at high risk for cardiovascular events, under ACC/AHA guidelines):</p> <p>1) Patients aged <math>\geq</math> 21 years at the beginning of the measurement period with clinical ASCVD diagnosis.</p> <p>2) Patients aged <math>\geq</math> 21 years at the beginning of the measurement period who have ever had a fasting, or direct laboratory result of LDL-C,</p>	N/A



Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre- population Source from 2018 UDS*	Denominator Description	Denominator Pre- population Source from 2018 UDS*
	<ul style="list-style-type: none"> <li>• Adults aged <math>\geq 21</math> years who have ever had a fasting, or direct low-density lipoprotein cholesterol (LDL-C) level, <math>\geq 190</math> mg/dL or were previously diagnosed with, or currently have an active diagnosis of familial or pure hypercholesterolemia; OR</li> <li>• Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL</li> </ul>				<p><math>\geq 190</math> mg/dL or were previously diagnosed with, or currently have, an active diagnosis of familial or pure hypercholesterolemia.</p> <p>3) Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and with an LDL-C result of 70-189 mg/dL recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period.</p> <p><i>Except</i> Patients who are pregnant, breastfeeding, have a diagnosis of rhabdomyolysis, adverse effect, allergy, or intolerance to statin medication; have active liver disease or hepatic disease or insufficiency, have end stage renal disease, most recent fasting or direct LDL-C laboratory test result <math>&lt; 70</math> mg/dL and are not taking statin therapy, or receiving palliative care</p>	

Focus Area (e-CQMs reference)	Performance Measure	2019 Revision <sup>1</sup>	Numerator Description	Numerator Pre-population Source from 2018 UDS*	Denominator Description	Denominator Pre-population Source from 2018 UDS*
<b>Financial Performance Measures</b>						
BPHC Health Center Program Grant Cost Per Total Patient (Grant costs)	Ratio of total BPHC section 330 grant funds per patient served in the measurement calendar year	No	BPHC section 330 grants drawn-down for the period from January 1 to December 31 of the measurement calendar year	T9E, L1g, CA	Total number of patients	T4, L6, CA
Total Cost Per Total Patient (Costs)	Ratio of total cost per patient served in the measurement calendar year	No	Total accrued cost before donations and after allocation of overhead	T8A, L17, CC	Total number of patients	T4, L6, CA
Medical Cost Per Medical Visit (Costs)	Ratio of total medical cost per medical visit in the measurement calendar year	No	Total accrued medical staff and other medical cost after allocation of overhead, excluding medical lab and x-ray cost	(T8A, L1, CC + T8A, L3, CC)	Medical visits, excluding nurse visits	(T5, L15, CB – T5, L11, CB)

<sup>1</sup> Information reflects revisions that significantly alter comparisons and where data cannot be compared between years.

\*Source notation: The formula references specify the table, line, and column from the 2018 UDS Reporting Manual

(<https://bphc.hrsa.gov/sites/default/files/bphc/datareporting/reporting/2018-uds-reporting-manual.pdf>) and are abbreviated as follows:

- T=Table
- L=Line
- C=Column